

HEALTHCARE INVESTOR BRUNCH

JAN 11, 2026

11:00 AM - 1:30 PM PST

SAN FRANCISCO, CA

Hosts

Big Idea
CONNECTpreneur

 opus8

Agenda

Sunday, January 11, 2026

11:00 - 12:00 am - REGISTRATION / NETWORKING

12:00 - 12:30 pm - WELCOME REMARKS & COMPANY INTROS

Opus8/CONNECTpreneur - Tien Wong

MTEC - Commander Christopher Steele

Gunderson Dettmer - Adrian Rich

Exhibiting Companies:

Actuated Medical - Maureen Mulvihill

Alphyn Biologics - Neal Koller

ARC Medical - Chris Springate

I-Lumen Scientific - John VeLure

KAHR Bio - Tomer Cohen

NeuroEM Therapeutics - Chuck Papageorgiou

ODNASS - Velimir Pajic

Pharma *in silico* - François Arcand

12:30 - 1:30 pm - NETWORKING

Hosts



CONNECTPRENEUR

Founded in 2012, the Big Idea CONNECTpreneur Forum is a global community of over 25,000 CEOs, Entrepreneurs, VCs and angels, CXOs and other business leaders. CONNECTpreneur RocketPitch is the World's Largest monthly investor pitch event, mashing up 600 - 800+ top founders, investors and business leaders featuring awesome networking, newsmaking speakers, and a "Rocket Pitch" showcase of exciting early stage companies. These unique events are like none other due to the high quality of our attendees and participants, as well as our programming and unprecedented networking, which maximizes the experience for all of our attendees and sponsors. The CONNECTpreneur team also provides capital raising, mentorship and support to hundreds of entrepreneurs as well as investors and VC funds around the world.



OPUS8

Opus8 is a private investment firm. We invest in well-run companies in life sciences and tech-enabled services, and also provide high-level fundraising, strategy and business advisory services to clients on a select basis. In addition, Opus8 seeks to acquire well-run companies servicing the healthcare and life sciences industries in BPO, CRM, contact center, and marketing services.



TIEN WONG, CEO, OPUS8, INC.

Tien Wong is a private investor and technology entrepreneur focused on early- and growth-stage companies across life sciences, medtech, healthtech, and technology-enabled services. He is Chairman & CEO of Opus8, a capital strategy and investment firm advising founders, boards, and investors on financing, growth, and strategic positioning. He serves as Executive Chairman of CONNECTpreneur and the New York Private Equity Forum (NYPEF), private capital platforms convening accredited investors, family offices, and operators around vetted opportunities. Tien is a Venture Partner with IronGate Capital Advisors and a member of the Investment Advisory Board of Virginia Venture Partners, and has arranged or advised on capital from leading institutional investors, family offices, and strategic allocators globally.

Sponsors



GUNDERSON DETTMER

Gunderson Dettmer serves market-leading venture capital and growth equity investors and pioneering companies through inception, growth and maturity, as well as groundbreaking public companies that result from the global venture capital ecosystem. We've maintained that focus for more than 30 years.

Our Life Sciences team of more than 50 lawyers works with companies and investors innovating in every segment of the life sciences space, including medical devices, tools, diagnostics, therapeutics, and healthcare IT.



MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM (MTEC)

MTEC is a DoD-focused nonprofit that funds medical technology development. We operate under a government-awarded Other Transaction Agreement (OTA)—a flexible contracting vehicle that allows us to move faster, collaborate more freely, and engage a broader range of innovators.

We drive military-civilian partnerships and foster collaboration within an extensive ecosystem of small and large businesses, federal agencies, academic institutions, and more. We rapidly deploy funding and drive innovative medical technologies that improve military and civilian health globally.



G U N D E R S O N D E T T M E R

Clear Leader for Life Sciences

#1 Most Active VC Law Firm Globally

2013-2024 Annual League Tables

#1 in Healthcare Devices

#3 Across All Life Sciences Categories:

Healthcare Devices & Supplies,
Healthcare Services & Systems, Pharma & Biotech

Q3 2025 Global League Tables



Adrian Rich
Partner



Angela Griggs
Associate



Advancing Medical Innovation



We advance the rapid deployment of innovative medical technologies that improve the health of the military and civilians.

\$1.5B

in government medical R&D funding through MTEC

\$1B

of additional external funding, creating significant government leverage

Benefits of MTEC Membership

Access to multiple funding opportunities through both government and MTEC's independent funding.

Access to membership partnering opportunities and expanded networking with federal agencies, researchers, industry leaders, and private investors.

Guidance from business, legal, accounting, and other subject matter experts (M-Corps) to support product commercialization.

Protection of innovations and strengthening of competitive position through intellectual property assessments and safeguards.

Focus Areas

Medical Training & Health Information Science

Chemical, Biological, & Radiological Threats

Clinical & Rehabilitative Medicine

Military Operational Medicine

Military Infectious Diseases

Combat Casualty Care

Open Funding Opportunities as of January 2026

Defense Health Agency (DHA)

Single Blood Donor Collection and Storage Bags Manufactured in Continental United States (CONUS)

Due Date: January 30, 2026

MTEC

MTEC Prototype Acceleration
Bridge Loans

Status: Open

See more funding opportunities at mtec-sc.org/solicitations

Scan for a digital copy of the MTEC Annual Report



Scan to Join MTEC



Partners



AMERICAN BUSINESS DEVELOPMENT

American Business Development (ABD) serves as a U.S.-based, outsourced business development and advisory partner for B2B professional services organizations, with a strong focus on life sciences. We help companies build structured, scalable pipelines by aligning business development operations, marketing, alliance management, and strategic programming. Our approach is human-centered and relationship-driven, emphasizing trust-building, clear positioning, and disciplined execution rather than transactional sales tactics. Whether developing a formal Business Development Plan® or representing clients at key industry conferences, ABD provides the infrastructure, expertise, and U.S. market presence needed to generate qualified leads and support long-term growth.



ANGEL LAUNCH

Angel Launch (www.Angellaunch.com) is based in Silicon Valley, and a leading producer of business summits for tech startups, investors, corporate executives, and tech professionals. The founder is Zahava Stroud, a retired attorney who has a huge personal network of investors actively seeking promising startups. We connect early to advanced stage startups with accredited investors through high-energy networking events, venture forums, VIP dinners, summits and demo to facilitate funding and business growth, with startups pitching judges on the stage and hosting a demo table.

We attract high net worth angels, VCs, corporate investors and family offices. Our market sectors include: AI, Deep tech, SaaS, Enterprise, cleantech, consumer, healthtech, medtech, Pharma and life sciences. We produce monthly events for 300-500 attendees in Palo Alto and San Francisco, and also before major trade shows like CES, Tech Crunch Disrupt, RSA and JP Morgan Healthcare week. We focus on high-level deal-making and fostering connections for startups seeking millions in funding. Most events are free to attend and hundreds of startups have formed deals to receive funding or partnerships in the past 12 years. For info send email to: info@angellaunch.com or call 310 6216i850.



BIOBUZZ

BioBuzz is a life sciences media and workforce solutions company that builds community, amplifies industry voices, and connects top talent with mission-driven employers. With a focus on regional ecosystems and emerging biotech markets, BioBuzz delivers impactful storytelling, employer branding, and talent engagement strategies that help life sciences companies grow and thrive.

Through a unique blend of content, community, and connections, BioBuzz is redefining how the industry communicates, collaborates, and competes for talent.

Executive Summary

American Business Development (ABD) is a U.S.-based business development advisory and execution firm that helps professional services, life sciences, and technology organizations build scalable, cost-effective pipelines in the U.S. market, APAC and MENA regions. ABD operates at the intersection of strategy, operations, and execution—serving as both a trusted advisor and an outsourced business development team.

ABD is founded on a core belief that effective business development is human-centered. Sustainable growth is driven by trust, credibility, and meaningful relationships—not mass automation, spam outreach, or transactional sales tactics. As such, ABD integrates sales discipline, consulting rigor, and technical fluency to help clients engage the right prospects at the right time with the right message.

At the center of ABD’s methodology is the Business Development Plan®, a tailored, institutional framework that defines how an organization generates leads, communicates value, manages relationships, and converts opportunities into revenue. This plan aligns business development operations with marketing, programming, alliance management, and export strategy—ensuring consistency across messaging, outreach, and execution. ABD then supports implementation through hands-on execution, training, and ongoing optimization.

ABD’s services span three primary areas:

Business Development Strategy & Operations

ABD designs and optimizes end-to-end BD systems, including SOPs, CRM architecture, pipeline stages, roles and responsibilities, outreach processes, and performance metrics. This work transforms ad hoc or founder-led sales efforts into repeatable, scalable operations.

Outsourced U.S.-Based Business Development

ABD acts as an extension of a client’s team, representing organizations in the United States without the cost, risk, or delay of hiring full-time staff. This includes targeted outreach, alliance development, CRM management, and full-cycle follow-up through qualified handoff.

Conference Representation, Programming & Partnerships

ABD leverages conferences, webinars, panels, and strategic programs as trust-building platforms rather than standalone events. The firm manages pre-event strategy, on-site representation, and post-event follow-up to convert visibility into measurable pipeline growth.

Across engagements, ABD delivers tangible value through significant cost savings compared to internal hires, accelerated market access through established U.S. networks, improved conversion rates through refined messaging and positioning, and durable internal capabilities that remain with the client long after an engagement concludes.



BioBuzz Networks, Inc.

BioBuzz is a category defining life sciences industry platform built on a AI-powered talent marketplace and community platform. We are transforming how regional biotech employers hire talent, how industry professionals connect, and how regional markets foster stronger ecosystems.

The Problem

Life science companies require niche resources to grow, but are constrained by broken staffing models, high recruitment costs, and fragmented ecosystems that silo talent and resources —especially in emerging biotech hubs.

Our Solution

BioBuzz delivers a powerful three-part platform that integrates to generate deep industry data and insights that we use to deliver agentic solutions with personalization.

1. **Talent Marketplace** that directly connects job seekers with employers, reducing time-to-hire and recruitment costs - focused on fractional and 1099 consultants.
2. **Media and Events** through digital media, storytelling, events and personalized resources we attract highly engaged community members and users.
3. **Ecosystem Amplification** that leverages partnerships with economic development to deliver regional workforce and industry strategies at scale.

Traction:

- \$450K revenue in 2025 from media & sponsorships
- 35+ paying clients across Maryland, Pennsylvania, and North Carolina
- 30,000 community members, 2,800 beta users in our talent marketplace
- First large-scale regional grant-based solution sold (\$225K) in Maryland

Revenue Model:

- Talent Marketplace: % fee per hire, membership fees and subscriptions.
- Digital Media & Sponsorships revenue
- Partnership Revenue: Referral-based income with strategic partners
- Grant-Funded Ecosystem Solutions: \$250K–\$500K per regional contract

Market Opportunity

The U.S. life sciences staffing and consulting market is \$11B annually, and freelance / fractional work is rising by double digits. As an alternative to traditional staffing, we're forecasting \$60M annual revenue in five years.

Seed Round: We are raising **\$750,000** to:

- Accelerate the build-out of our talent marketplace platform
- Expand sales and business development to support geographic growth
- Enhance ecosystem data tools and community engagement features

Exhibitors



ACTUATED MEDICAL

Actuated Medical, Inc. is transforming tools for brain access, delivery, and performance. Our NeuralGlider technology uses electronically controlled micro-motions to access the brain to improve precision, reduce tissue trauma, and enhance outcomes. Preclinical studies have shown that NeuralGlider can deliver brain implants with better trajectory control and inject biologics more accurately into deep brain targets. NeuralGlider has gained early traction: 39 global research labs users, generating around \$500K in sales, with citations in 43 third-party publications. NeuralGlider is compatible with over 15 implant designs, far more than our closest competitor. Brain researchers are building the science to move NeuralGlider into clinical applications. Actuated Medical is working with premier academic institutions to improve Deep Brain Stimulation (DBS) probe insertion - reducing the need for revision surgeries. NeuralGlider's precise control can also be a key factor with thin cannula placement to deliver biologics like cancer treatment to deep brain targets - impacting billion-dollar markets.

ALPHYN BIOLOGICS

Alphyn is advancing unique patented natural topical drugs from its first-of-a-kind single-source plant-derived drug platform that provides Multi-Target Therapeutics®, an innovation that has multiple bioactive compounds, therefore multiple mechanisms of action, to uniquely target the multiple interconnected causes of diseases. Our lead drug candidate for atopic dermatitis has completed Phase 2 trials with competitively superior results, positioning to be the first drug to directly target AD's 4 problems - itch, inflammation, bacteria, and dry skin. Our second drug candidate for molluscum contagiosum virus directly treats this disease's multiple problems - the virus itself, itch, inflammation and in certain patients dermatitis (molluscum rash) and bacterial infection with its associated pain. It has successfully completed the Phase 2 clinical trial program, demonstrating strong safety and efficacy compared to current therapies. Alphyn's drugs have a robust safety, side effect, and patient tolerability profile, especially versus current options, supporting worry-free use.



ARC|Medical **ARC MEDICAL**

ARC is preventing orthopedic and abdominal & gynecological surgical adhesions with the Company's clinical stage, JOCOAT™ and IPCOAT™ liquid adhesion barrier medical devices. Surgical adhesions are a large, unmet medical need with a total addressable market of greater than 11M patients and \$11B annually. JOCOAT™ and IPCOAT™ are easily and rapidly used in multiple types of arthroscopic, arthroplasty, laparoscopic and open surgeries; and are backed by favorable surgical patient data, positive safety clinical trial data, and 5+ patents granted in each of the US and Japan that provide exclusivity through 2039+. ARC has raised \$21M in equity and an additional \$18M in non-dilutive revenues and grants. ARC is now treating patients with JOCOAT™ in an orthopedic knee anterior cruciate ligament (ACL) repair surgery patient clinical trial and initiating a clinical trial for IPCOAT™ in gynecological endometriosis surgery patients. These two clinical trials are expected to provide topline data in H2 2026 and initial approvals and revenues in H2 2027 in Europe, the Middle East, Southeast Asia and Oceania.

Exhibitors



I-LUMEN SCIENTIFIC

i-Lumen Scientific is a new physician delivered therapeutic for dry age-related macular degeneration. The i-Lumen® AMD System is an office-based, non-invasive therapeutic for intermediate to advanced dry AMD - a disease that leads to central field vision loss and is the leading cause of blindness in those over 55. Our proprietary ocular stimulation therapy repolarizes retinal pigment epithelium (RPE) cells and restores photoreceptor cell function, improving visual acuity and slowing disease progression. With commercialization projected in 2028 following FDA clearance, i-Lumen is raising a Series B round (\$35.0M) to fund its i-SIGHT2 Pivotal Trail (multi-country) and complete the development of a commercially-ready system.



KAHR BIO

KAHR Bio develops dual-targeting fusion protein therapeutics designed to activate both the innate and adaptive immune systems while localizing activity within the tumor microenvironment. The company's multifunctional fusion proteins aim to drive coordinated and durable anti-cancer responses. The company's lead asset is DSP107, a first-in-class, bi-specific 4-1BB-targeted, next-generation T-cell engager. The Company is based in Modi'in Israel and conducts its clinical trials at US and Australian medical centers.



NEUROEM THERAPEUTICS

NeuroEM Therapeutics is advancing brain health and the treatment of neurodegenerative disease through non-invasive, device-based innovation. Built on more than a decade of peer-reviewed research and clinical investigation, the company is focused on addressing the underlying biological drivers of cognitive decline rather than managing symptoms alone. NeuroEM's core innovation, Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF), is designed to target toxic protein aggregation, neuroinflammation, and impaired cellular energy, which are key mechanisms implicated in Alzheimer's disease and related disorders. The technology is delivered through a wearable headset intended for safe, repeatable at-home use. NeuroEM's momentum is reinforced by the FDA's first-ever Breakthrough Device designation for Alzheimer's disease, a strong and defensible intellectual property position, and recognition as part of StartUp Health's Alzheimer's Moonshot Community. The company's capital-efficient model pairs a therapeutics-first strategy with a wholly owned consumer subsidiary pathway that validates demand, generates real-world data, and helps fund and de-risk clinical development. Led by an experienced management team and guided by a distinguished medical advisory board, NeuroEM is positioned to bring life-changing treatments to market and offers investors a compelling opportunity to support transformative healthcare innovation addressing one of the most urgent and costly challenges in global healthcare.

Exhibitors



ODNASS

Odnass is a next-generation early cancer detection company developing a rapid, blood-based screening platform designed for real-world clinical and population-level use. The Odnass approach focuses on detecting cancer at the earliest, non-symptomatic stage by analysing cell-free DNA (cfDNA) signals using advanced physical detection methods combined with machine learning and graph-based models. Rather than relying solely on sequencing-heavy workflows, Odnass is being engineered to deliver faster turnaround, lower cost, and greater scalability, with the goal of expanding access beyond specialist centres and first-world healthcare systems.

From inception, Odnass has been built with a clear emphasis on clinical practicality, robust IP protection, and global deployability. The platform is intended to support early risk identification and triage, enabling earlier intervention and improved outcomes while reducing systemic healthcare burden.

Odnass is currently advancing its scientific validation and IP strategy, and is engaging with select investors and strategic partners to support its next phase of development toward clinical and commercial translation.



PHARMA IN SILICA

Poison the tumor, spare the patient

Pharma *in silica*'s precision chemotherapy attacks solid tumors while sparing patients the painful, maiming and costly adverse effects imposed by the current standard of care.


Our first product, OpPacli™, is fifteen months to a FDA Phase Ib/IIa clinical trial under 515(b)(2) against NSCLC, a lethal lung cancer.

Starting in 2028, the proprietary nanocarrier platform will enable pharmaceutical partners to capture the \$25 billion market of cytotoxic drugs and ADCs.

Transformative Tools for Neural Access, Delivery, & Performance

INITIAL CLINICAL MARKET

Improving DBS Probe Placement – Minimizing Revision Surgeries for Treatment Resistant Neurological Conditions




Since 2006, Actuated Medical has been dedicated to improving patient outcomes by integrating motion into medical devices. Developed with \$18M in non-dilutive funding, our **NeuralGlider®** technology uses gentle oscillation for less invasive brain implant insertion and targeted drug delivery. We're tapping into multi-billion-dollar neurological disease treatment markets – including treatment-resistant addiction, depression and Parkinson's Disease. Our **NeuralGlider Inserter** inserts brain implants with greater precision and less tissue damage to improve implant performance and longevity. The **NeuralGlider Injector** enables targeted drug delivery deep into the brain with finer, less invasive needles to minimize tissue trauma and medication loss for brain cancer treatment, AAV-gene therapy infusion, and addiction treatments. 43+ third-party publications citing NeuralGlider are strengthening the scientific foundation to transition to clinical indications. Our first clinical indication intends to improve deep brain stimulation (DBS) probe insertion, reducing clinician variability and the need for revision surgeries, demonstrated initially in Parkinson's patients.

Problem

100M+ People globally have treatment resistant neurological conditions, such as Parkinson's Disease, epilepsy, obsessive-compulsive disorder (OCD), and depression.

DBS can give them their lives back, when other treatments fail.


Complex tissue dynamics result from the many different tissue layers in the brain that the probe transverses. Therefore, as DBS probes are inserted, 3-8% of the time the probe tip misses the target (~1 in 20 patients), or shifts after the tip is put in place, leading to off target effects, sub-optimal treatment, or potentially a costly second brain surgery.



Solution

NeuralGlider uses patented gentle oscillating technology and a coupling mechanism to insert brain implants precisely with less force and damage to tissue.

Preclinical studies have shown the ability to hit small targets in the brain more accurately resulting in improved implant performance and outcomes.



Market Size

DBS, BCI Systems, Next Gen Probes

NeuralGlider INSERTER DBS \$1.5B CAGR 9.8%

Addiction, Gene Therapy, Cancer Medication Infusion

NeuralGlider INJECTOR AAV \$3.9B CAGR 40.1%



\$50M+ Non-Dilutive Capital

9 FDA 510(k) Clearances

45 US & Intl Patents

11 Registered Trademarks



ISO 13485 Certified



20,000 sq ft Facility

2006 est. PA C-Corp

Management Team



Maureen Mulvihill, PhD
President & CEO

Board Member of



Roger Bagwell, PhD
Director, Neural Device Operations



Douglas Dillon, MS
Director, QA & RA



Ian Charney
Director, Manufacturing



Christian Haller
Advisor

MAB

11 Members

BOD

5 Members

Keiretsu Key Deal Terms

- + \$10M Series A
- + Participating Preferred Shares
- + Warrants Discounted 50%
- + \$25k Minimum Investment
- + QSBS Entity Structure
- + \$25M Pre-Money Valuation

Let's Talk!

Maureen L. Mulvihill, PhD | CEO
maureen@actuatedmedical.com
814.355.0003 x100

ActuatedMedical.com



Alphyn Executive Summary

Breakthrough Drug Platform – Drugs of Choice for Large Poorly Served Diseases

Multi-Target Therapeutics™
A New Class of Drugs
More Powerful Therapeutics

MANAGEMENT TEAM

Neal Koller – Chairman & CEO
President & CEO, Board of Directors, life science businesses, last exit at 16x; Sr. Exec. Wyeth

Gary Pekoe, PhD - Chief Scientific Officer
Director multinational pharma companies, led development & approval of 1st / market leading topical antibiotic **Bactroban**®, led clinical trial protocol writing team for **Keytruda**®

James Darnell – Vice President, Quality
30+ years pharmaceutical, biotech, medical device Quality & Regulatory leadership

Steven Pentelink – President
P&G Exec. managed **\$1B early tech portfolio**, global manager \$750M Beauty Care Products

Jazmyne Mink – Regulatory Affairs Manager
10 years' experience with Alphyn's zabalafin

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab
Emery Pharma - Chemistry & Microbiology Lab
World Class Ethnobotanist
World Class Botanical Chemistry & Analytics Lab
DDL - Formulation and Manufacture
PCCA - Formulation and Manufacture
Multiple Geo-local Agri Partners
Accelagen - Regulatory & Clinical Trials (AU)
MMS & Precefi - Regulatory & Clinical Trials (US, LA)
Tech Edge - Regulatory & Clinical Trials (EU)
DLA Piper - IP & Legal Worldwide
EisnerAmper - Finance & Tax (US)
Artus GmbH - Finance & Tax (EU)
RDI Partners - Finance & Tax (AU)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD
Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ

Peter Coderre
FDA IND & NDA Microbiology Reviewer (retired)

Patric Lundberg, PhD
Past Assoc. Prof, Micro/ Cell Biology, E. VA Medical School

Shekhar Mitra, PhD
Sr VP, Global Innovation, Procter & Gamble (retired)

PREVIOUS FUNDING

Founders \$ 870 K (not capitalized)
Seed \$ 1.1 M (Convertible Note)
Pre-equity \$ 2.5 M (Convertible Note)
Series A \$ 5.5 M (Preferred Stock)
Series B \$25.0 M (Preferred stock)
Oversubscribed

FUTURE FINANCING

Series C or Partnering or IPO:
Complete AD Phase 3 Clinical trials
Complete MCV Phase 3 Clinical Trials

COMPANY OVERVIEW

Alphyn's unique Zabalafin drug platform is a superior technology that will change the way skin diseases are treated. Drugs from the Zabalafin platform will become "Drugs of Choice". Initial diseases to be treated, **Atopic Dermatitis (AD)** and **Molluscum Contagiosum Virus (MC)**, have huge patient populations in need of much better therapeutics. Only Zabalafin directly treats all the problems of each of these diseases. Zabalafin is a new class of drugs named Multi-Target Therapeutics™ because it has multiple mechanisms of action from multiple bioactive compounds. This allows Zabalafin drugs to treat a single disease in multiple ways, to be more effective, and treat multiple different diseases, for a rich new product pipeline. Zabalafin is a natural drug that is patient preferred. It is not a steroid and is not expected to have FDA box warnings, as some competitor drugs are and do. Due to Zabalafin's strong safety, low side-effect, and excellent patient tolerability profile, it is anticipated to be the first drug for AD and MC that can be used worry-free for long term and continuous use.

AD - THE PROBLEMS WITH CURRENT THERAPEUTICS

- Huge, poorly served market opportunity: Estimated at \$48 Billion Global, \$21 Billion US¹
- Steroids and Topical Calcineurin Inhibitors– Side effects and FDA Box Warnings
- Injectables – Painful, many side effects, not desirable for children
- Orals – FDA Box Warnings, not desirable; drug with FDA warnings circulates throughout body
- Topicals – FDA Box Warnings, side effects, not very effective

AD - TWO SUCCESSFUL PHASE 2a CLINICAL TRIALS: BETTER THAN COMPETITION

- Most important - itch relief superior to competition
- Only AD drug to directly treat itch and the critical Bacterial Component of AD
- 90% of patients report significant improvement in Quality of Life
- 35% better reduction in inflammation (IGA) versus dominant market leader
- Strong safety data; Phase 1 clinical trial not required. Phase 2 clinical trials start age 2

AD - PHASE 2b CLINICAL TRIALS: BETTER THAN COMPETITION

- Trial ongoing in Australia and Dominican Republic
- FDA IND open, clinical trial in the US to begin shortly
- Ongoing Phase 2b clinical trial results (interim, blinded) point to better than Phase 2
- Results (unblinded) expected March 2026

AD - ZABALAFIN RECOGNIZED AS BREAKTHROUGH THERAPEUTIC

- 3 peer-reviewed published papers support zabalafin as the dermatologists' drug of choice ^{6, 7, 8}
- "... through its multiple mechanisms of action, zabalafin targets all components of ... AD ...," ⁸

AD - STRONG COMPARABLE EXIT DEALS

Acquired / Licensed	When	Exit: Cash plus Milestones	Exit Stage
Yellow Jacket (by J&J)	July '24	\$1.25 Billion	Pre-Phase 2 Clinical Trial
Proteologix (by J&J)	May '24	\$850 Million + Milestones	Pre-clinical
Kyowa Kirin (by Amgen)	Jun '21	\$1.25 Billion	Phase 2 clinical trial
Kymab (by Sanofi)	Jan '21	\$1.45 Billion	Phase 2 clinical trial

MC - THE PROBLEMS AND ZABALAFIN SOLUTION IN TREATING MC

- Huge, poorly served market opportunity: Estimated at \$22 Billion Global, \$13 Billion US¹
- All approved therapies are skin destructive and painful
- Zabalafin Proof-of-Concept trials show strong efficacy and excellent safety, patient tolerability
- Phase 2 clinical trial to begin shortly, results (unblinded) expected May 2026

MULTIPLE MARKET PROTECTION STRATEGIES

- US & European patent protection to 2042; with additional global filings
- Regulatory exclusivity possible: 10 years USA FDA, 8 years Europe & Japan
- Currently no FDA generic drug approval path - Expect no generic drug competition
- Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory

ARC|Medical

Raising \$5M to support pivotal clinical trials
for approvals and sales in EU, MENA, SEA, Oceania and Canada

ARC improves surgical patient recovery by preventing internal adhesions

What are surgical adhesions?

- #1 The most common surgical complication
- Form during first 5 days after surgery
- Adhesions are internal scars



≥ 31% of gynecological, obstetric and abdominal patients get adhesions



≥ 5% of knee and shoulder surgery patients get adhesions


Jane's knee adhesions stopped her from doing activities she loves



▶ Watch
JOCOAT™
application

IPCOAT™

Prevents gynecological and abdominal surgical adhesions



Successful Phase 1 Trial (N=76)
Treated Surgical Patients (N=1)

✓ Clinical Safety

Open Laparotomy and Laparoscopy

Just 2 mL / kg body weight

< 2 minutes to apply

Now : Initiating efficacy + safety clinical trial (N=33)

JOCOAT™

Prevents shoulder and knee surgical adhesions



Treated Surgical Patients (N=20)
Knee and Shoulder

✓ Clinical Efficacy + Safety

Open and Arthroscopy

Just 10 mL of JOCOAT™ per joint

< 1 minute to apply

Now : Efficacy + safety clinical trial (N=74)

7 Patent Families plus Trade Secrets
Provide exclusivity through 2039+



Japan: 5



US: 5



Patents granted and/or pending in
> 10 additional key territories

135 degrees range of motion post surgery + JOCOAT™ :
"I got my life back!"



A New Physician Delivered Therapeutic for Dry Age-Related Macular Degeneration.

The i-Lumen® AMD System is an office-based, non-invasive therapeutic for intermediate to advanced dry AMD—a disease that leads to central field vision loss and is the leading cause of blindness in those over 55.

Our proprietary ocular stimulation therapy repolarizes retinal pigment epithelium (RPE) cells and restores photoreceptor cell function, improving visual acuity and slowing disease progression.

With commercialization projected in 2028 following FDA clearance, i-Lumen is raising a Series B round (\$35.0M) to fund its i-SIGHT2 Pivotal Trial (multi-country) and complete the development of a commercially-ready system.

i-Lumen Delivers Clinically Meaningful Vision Improvements (i-SIGHT study):

- 54% improved BCVA by ≥ 10 letters and maintained improvement out to 12 mths
- 39% mean increase in ellipsoid zone (EZ) integrity (a mitochondria-rich layer that is an energy source for photoreceptor cells)
- 21% increase in photoreceptor cell light-processing speed
- 14% increase in signal strength generated by photoreceptor cells

No other energy-based therapy has demonstrated these levels of improved response in such a short period of time and sustained it through 12 months.

Dry AMD Market represents a huge Opportunity:

- 200.0M people globally suffer with AMD, more than 20.0M in the US alone
- Dry AMD market projected to be \$68.0B by 2029

Established Acquisition Benchmark – \$850.0M Pre-Revenue Sale:

- Alcon acquired LumiThera, Inc. for an estimated \$850.0M
- LumiThera's Velada is an inferior energy-based device therapy for dry AMD
- This acquisition underscores the industry's focus on energy-based therapies like the i-Lumen® AMD System, a scalable physician-based revenue model

Path to potential Exit in 2028:

- i-SIGHT2 Pivotal Trial data availability – projected for mid-2027
- Submission to FDA for market clearance – projected for late 2027
- Re-engage ophthalmology targets (Alcon, B+L, J&J, etc.) – projected for 2028

i-Lumen represents an investment opportunity in ophthalmology with a projected exit in 2028.

Contact: John VeLure (CEO/President)

Address: 3800 American Blvd. West, Ste. 1500 Bloomington, MN 55431

Phone & Email: 952-240-6023 / jvelure@i-lumen.com

Quick Facts

Company Name:

i-Lumen Scientific, Inc.

Industry: Ophthalmology

Domain: Medical Device

Target Market: Dry Age-Related Macular Degeneration

General Counsel & Patent:

Fox & Rothschild

29 US Patents, 3 CN Patent, 3 EU Patent, 2 AU Patent

Auditor: Baker Tilly US, LLP

Series B Funding Round: \$35.0 M

Current Investors:

Bios Partners (lead investor), MedFocus, and Alafi Capital

Use of Funds:

i-SIGHT2 Pivotal Study, Develop Commercially-Ready System, FDA Market Clearance, Reimbursement

Deal Terms:

Series B Funding Round
Convertible Preferred Stock
8.0% Cumulative Dividend
Share price: US\$1.35

Valuation:

Pre-money: US\$31.5M
Post-money: US\$69.3M

Investment Options:

Direct: US\$500K minimum
SPV: US\$50K minimum

Key Leadership Team:

John VeLure (CEO/President)
Meredith Mundy (Research)

Industry-based Board Members:

Robert Warren (Alcon)
Stella Robertson (Alcom)

www.i-lumen.com

KAHR Bio: Turning the Promise of Immunotherapy Into a Reality for Colorectal Cancer Patients



Key Opportunity Highlights:

- ✓ DSP107, KAHR Bio’s lead program, improved patients’ survival using a well-tolerated and chemotherapy-free regimen in a phase 1/2a trial in late-stage Microsatellite Stable Colorectal Cancer (MSS CRC)
- ✓ MSS CRC is the second largest cause of cancer deaths worldwide and represents a market opportunity of more than \$15bn per year
- ✓ KAHR Bio raised a \$22mm Series B round in October 2025 to fund a randomized, controlled phase 2b trial (n=86) in fourth line patients which initiated in December
- ✓ KAHR expects to have data from the phase 2b trial in late 2027, at which point KAHR would be a logical candidate for an acquisition or IPO
- ✓ The Series B round is open for a deferred close of up to \$10mm until June 2026

Corporate Summary

KAHR Bio is developing multifunctional fusion proteins that boost the immune systems’ response to cancer. The Company is based in Modi’in Israel and conducts its clinical trials at US and Australian medical centers. KAHR is backed by Israeli, European and Asian life science VCs and is NASDAQ IPO ready

KAHR Differentiation From Existing Late-Stage Therapies


	Existing	DSP107
Technology	Chemotherapy or multi-kinase inhibitors	Immunotherapy that create a precise therapeutic effect
Activity	Systemic	Only in the tumor
Safety / Tolerability	Toxic	Very well-tolerated with minimal side effects
Efficacy	Median survival: < 11 months	Median survival 17.5 months

Mechanism Uniquely Suited to MSS CRC

- DSP107 utilizes CD47 over-expression on cancer cells to anchor a 4-1BB ligand to those cells, thereby attracting and activating cytolytic effector t-cells
- CD47 expression increases in liver metastases following chemotherapy, creating a therapeutic window uniquely addressable by DSP107.
- Liver mets are present in 70-80% of metastatic CRC patients

Market Opportunity

2025 Annual Incidence
US / 5 Major European Markets¹



Investment Opportunity

- KAHR’s Series B round in October 2025 was priced at a pre-money of \$50mm, a significant discount to the only other “pure play” in late-stage fourth-line CRC regardless of liver met status, CytomX (market cap: \$700mm)
- The round is open for a deferred close of up to \$10mm
- Additional capital would be used to:
 - Increase the size of phase 2b trial
 - Prepare manufacturing for a phase 3 trial
 - Extend the company’s runway

Exit Strategy

- KAHR believes it will be positioned for an acquisition following a successful phase 2b, as large pharma companies are interested in assets that treat common cancers such as CRC
- KAHR is also public-ready and could pursue an IPO to fund a phase 3 trial on its own
- Recent comparable acquisitions suggest an attractive return for investors:⁵

Year	Acquirers	Sellers	Deal Value (\$mm)		Phase
			Total	Upfront	
2025	Lyell	ICT	894	74	Phase I
2025	Roche	Hansoh	1,530	80	Phase I
2023	Takeda	Hutchmed	1,130	400	Phase III
2021	Pfizer	Trillium	2,260	2,260	Phase I/II
2020	Gilead	Forty Seven	4,900	4,900	Phase I
2020	AbbVie	I-Mab	1,940	180	Phase I
		Median	1,735	290	

1. Major European markets represent UK, France, Germany, Italy, Spain
 2. GlobalData
 3. Wall Street Estimates and Company Estimates
 4. Assumes annual cost of therapy of \$125k / \$65k for US / EU
 5. Includes all single-asset phase I or II deals in CRC, NSCLC, or for CD47 targeting agents since 2020



NeuroEM's first-of-its-kind device offers a safe, effective, and non-invasive approach to treating neurodegenerative diseases, including Alzheimer's, and protecting brain health throughout the aging process.

www.NeuroEM.com

Alzheimer's is among the costliest conditions to society

- Worldwide, **55M people are living with Alzheimer's**.
- More than **7.2M Americans** have Alzheimer's. **500,000+ are diagnosed each year**.
- Medicare spends 3 times more** for beneficiaries with Alzheimer's.

NeuroEM will be a disruptive force in the Alzheimer's therapeutics market

There is no cure and treatment options are ineffective and difficult for patients and cost thousands of dollars per year.

- 5 of the 8 FDA-approved drugs do not affect the underlying brain changes that cause symptoms. **None are right for all patients**.
- Ongoing research exploring potential pharma options **remains uncertain**.


Human clinical studies showed cognitive stabilization or improvement in 7 of 8 AD sufferers within 2 months

Our Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) alters three key factors at the root of cognitive decline:

- Detoxify the brain by disaggregating toxic A β and p-tau proteins
- Rebalance cytokines, indicating a reduction of inflammation in the brain and body
- Increase ATP—the source of energy for use and storage at the cellular level

Capital investment to date: \$9M+

Target Milestones



Investment Opportunity

NeuroEM is raising two rounds over the next two years:

- \$5M Series A Preferred today** to prepare the final product for launch at a lower strategic pre-money valuation.
The first \$3.3M has closed, led by BlueLake.VC and Lunch Pail Ventures
- \$5-10M Series A1 Preferred in 2026** to launch the wellness product.

GLOBAL MARKET

ALZHEIMER'S THERAPEUTICS

\$11.3B

IN 2024

\$29.4B

IN 2035

DIGITAL BRAIN HEALTH

\$243.7B

IN 2024

\$478.6B

IN 2033

NOOTROPICS / SUPPLEMENTS

\$10.1B

IN 2024

\$17.6B

IN 2030

FROM RESEARCH TO COMMERCIALIZATION:

NeuroEM is transforming groundbreaking research into a commercially viable reality.

15+ Years of Research, with a nationwide **1,000-subject study launched in Q3 2025**.

Patent portfolio includes **10 issued US patents** and **approximately 20 associated applications globally**.

First to receive **FDA Breakthrough Device** status for the treatment of Alzheimer's

Received **FDA's 513(g) Determination**, confirming our strategy to release a DTC wellness product.

A **proven leadership team** and **medical advisory board** – with scientific and technology backgrounds, startup experience, and commercial expertise.

Startup Health **Alzheimer's Moonshot Community** Member



Contact

Chuck Papageorgiou, CEO
 Chuck@NeuroEM.com
 +1-727-252-6120



ODNASS
ONCOGENIC DNA SCREENING SYSTEM

Investor Executive Summary

Odnass Pty Ltd is developing a **next-generation early cancer screening platform based on direct quantification of cell-free DNA (cfDNA) from plasma** — a rapid, affordable, and scalable approach integrated with Artificial Intelligence (AI), Graph Neural Networks (GNN), and blockchain-enabled data security.

The platform is being **designed to support multi-cancer screening at the non-symptomatic stage**, with target performance metrics of under three hours total operational time (TOT) and a projected cost of below US\$100 per test, enabling broader accessibility and potential applicability for global population-level screening.

Value Proposition

A fast, affordable, and secure blood-based multi-cancer screening solution designed to identify cancer-associated biological signals at the earliest, non-symptomatic stage. Odnass operates through direct cfDNA quantification from plasma, avoiding sequencing and complex extraction workflows, and integrates AI- and GNN-driven analytics with blockchain-enabled data security. The result is a platform engineered for high accessibility, scalability, and rapid turnaround, supporting population-level screening use cases.

Company Background

Founded in Perth, Australia, Odnass is a MedTech and AI biotechnology company developing breakthrough early detection systems. Patent AU 2025902937 was filed in July 2025. Laboratory and validation infrastructure are established to commence Proof-of-Concept trials in Q1-Q2 2026 (Jan-June).

Leadership Team

Dr Velimir Pajic (CEO & Co-Founder) – Medical scientist and biotech entrepreneur with 25+ years of R&D experience; founder of Liquim Ltd and Ardaei. **Dr Tomaz Budefeld** (Co-Founder) – Scientist and clinician specialising in oncology and molecular diagnostics. **Dr Zeljko Perdija** (Co-Founder) – Medical doctor and researcher with experience in clinical medicine and cancer research. **Tadej Tofant** (Co-Founder) – Bioinformatics specialist in data-driven biological analysis and computational modelling.

Research and Development of the Odnass Test

Odnass is developing an early cancer screening platform based on direct cfDNA analysis from plasma, using AI-enhanced signal interpretation without sequencing or complex extraction, supported by blockchain-enabled data integrity and EMR integration.

Technologies / Special Know-How

Odnass is protected under a provisional patent covering its direct cfDNA detection chemistry, AI- and GNN-based predictive modelling, and blockchain-enabled data architecture. A proprietary bioinformatics framework and signal analysis methodology underpin the platform, creating meaningful barriers to entry and supporting long-term differentiation.

Market

Odnass is protected under a provisional patent covering its direct cfDNA detection chemistry, AI- and GNN-based predictive modelling, and blockchain-enabled data architecture. A proprietary bioinformatics framework and signal analysis methodology underpin the platform, creating meaningful barriers to entry and supporting long-term differentiation.

Distribution Channels

Odnass plans strategic licensing to Tier-1 MedTech partners (Roche, Guardant Health, Illumina, Exact Sciences) and diagnostic networks. Comparators include GRAIL (Galleri; 10–14 days, ~\$950), Quadrant Shield (7–10 days, ~\$1,200), and OncoSeek (3–5 days, ~\$145). Odnass targets ~3 hours and <\$100 per test, based on internal modelling and early validation assumptions. Financial Projection (Indicative Potential)

Global Potential (Full Scale)	Initial Regional Rollout
Annual Tests: 60 million	Annual Tests: 6 million
Price per Test: US \$100	Price per Test: US \$100
Potential Revenue: US \$6 Billion	Potential Revenue: US \$600 Million
Gross Margin: >70%	Gross Margin: >70%

Operational Readiness

Odnass plans strategic licensing. Odnass is entering its proof-of-concept phase with established laboratory infrastructure, active patent protection, and a multidisciplinary scientific team in place to execute controlled validation studies. The company's operational setup supports rapid iteration and data generation, positioning Odnass for early strategic partnerships and commercial pathway discussions as validation milestones are achieved.

Early Cancer Screening, Re-Engineered for the World

Direct cfDNA Detection, AI-Driven Predictive Modelling, with Blockchain-Enabled Privacy and Security

Quick Facts



Company Name: Odnass Pty Ltd
Contact: Dr Velimir Pajic, CEO
Address: Perth, WA, Australia
Email: velimir.p@odnass.com
admin@odnass.com
Website: www.odnass.com
Industry: MedTech / Biotechnology
Patent Estate: AU 2025902937 – Direct cfDNA Detection & AI/GNN Modelling + Blockchain
Financing Sought: US \$1.5M SAFE
Use of Funds: Proof-of-Concept.

Executive Summary

Laboratoires Pharma *in silica* inc.



One line pitch: poison the tumor, spare the patient

Business summary: we intend to fix a bad and often unavoidable medicine with our precision chemotherapy: our improved paclitaxel attacks solid tumors while sparing patients the painful, maiming, and costly adverse effects imposed by the current standard of care. OpPacli™, the first product candidate, is fifteen months to a phase Ib/IIa under 515(b)(2) against NSCLC, a lethal lung cancer. Starting in 2028, the proprietary nanocarrier platform will enable pharmaceutical partners to capture the \$25 billion market of cytotoxic drugs and ADCs and generate lucrative opportunities for shareholders.

Management: an agile mix of seasoned lifescience managers (financing, deal-making, early-stage product development, and licensing) and nanotechnology scientists (material science, pharmacology, animal studies, oncology), supported by expert consultants (process development, regulatory, IP, etc.).

Customer problem: current chemo brings limited improvements in survival and remission, in part because it disrupts the immune system, inhibiting the patient's natural ability to neutralize cancer cells. Chemotherapy also imposes painful, long-lasting, and costly side effects (anemia, infections, neurological disorders, discomfort, etc.). Almost no current research addresses this unmet need.

Product: our silica nanocarrier allows cytotoxic drugs to circulate extensively in the blood without affecting the biological activity of blood cells (red blood cells, neutrophils, HK, CD-8, and other lymphocytes) and delivers large quantities of cytotoxic agents specifically to the tumor.

Target market: all pharma companies committed to oncology.

Sales/marketing strategy: we will match the specific capabilities of our nanocarrier with the specific needs of pharmaceutical companies, using patents, scientific literature, network, and AI. Potential partners will be approached with a scientific and business case showing how our nanocarrier can specifically bring them value, such as the resurrection of promising programs failed during early development, returning cytotoxic drugs to blockbuster status, and improving under-performing oncology drugs.

Business model: we want to leverage our mastery of silica chemistry and early-stage product development to become a highly profitable product-candidate factory. The plan is a) to license our safe cytotoxic platform to pharmaceutical companies after human proof of concept, and b) to manufacture the development and commercial lots for our partners. Think of Debiopharm (organic chemistry) and abCellera (bivalent antibodies).

Competitors: Taxol® (1995) and Abraxane® (2005) are direct and technically inferior competitors, among the overall 17 B USD genericized market of cytotoxic drugs. ADCs (7 B USD) are another family of more recent proprietary products that could be displaced by our technology. Technically, we follow the potential threats from research groups and companies using silica (a small handful) and, more generally, micro and nanoparticles (many but few in injectable form).

Competitive advantage: the virtuous circle of reduced adverse effects allows for a healthier patient who completes her/his treatments and reduces the cost to all parties involved (patient, family, employer, insurers, hospitals, etc.). Strong and young IP position.

Company profile

URL : www.pharma-insilica.com

Industry: pharmaceuticals

Employees: 6

Founded: 2018

Contact

François Arcand

arcandf@Pharma-insilica.com

+1 (514) 994 1023

Financial information (USD)

Stage : IND-enabling preclinical

Previous capital: 3,6 M

Monthly net burn: 160 k

Capital seeking:

Preclinical round until April 2026:

1,5 M, pre-money valuation 10 M

Seed round 2026: 10 M, valuation to be established

Management

François Arcand, MBA, President & Co-founder

Myriam Laprise-Pelletier, PhD, Scientific Coordinator

Jean-François Haince, PhD, Product Development

Advisors

Nanotechnology: Prof. Nicolas Bertrand, PhD

Lawyer : Frédéric Docion, BCF


Accountant : Pascal Parent, Cofinia

Auditors : Enst Young

Investors

Dr. Michel L'Heureux, Alexandre Grenier and 15 other HNWI

Investissement Québec





BALTIMORE

FEB 5, 2026

NETWORKING & PITCH
EXTRAVAGANZA



Register Now!

[CLICK HERE](#)



WASHINGTON, DC

APRIL 16, 2026

NETWORKING & PITCH
EXTRAVAGANZA



Register Now!

[CLICK HERE](#)

CONNECTPRENEUR INVESTOR NETWORK:

VIRTUAL MEETING

Curated presenters.
Investors Only.

May 28, 2026 | 11am - 12pm ET

Register Now!

[CLICK HERE](#)



VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**206k business
leaders**
in our Community

[CLICK HERE FOR
THE IN-PERSON
BROCHURE](#)

[CLICK HERE FOR
THE VIRTUAL
BROCHURE](#)

Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**

[View the full
brochure here](#)

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

CONNECT with us!

